Table 1 Effects of disulfiram on cell apoptosis rates from in vitro studies
From: Anticancer effects of disulfiram: a systematic review of in vitro, animal, and human studies
Reference | Country | Tumor | Percentage of apoptosis (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Intervention time | Negative control | Posivitive control | Cell lines | Negative control | Positive control | Treatment group | |||
You et al. | China | Colorectal cancer | 48 h | Saline | DOX (8.5 μM) | HCT116 | 0.27 ± 0.24 | 29.2 ± 4.1 | DSF/Cu 0.05 μM: 8.55 ± 2.3, 0.1 μM: 24.02 ± 3.6, 0.2 μM: 38.4 ± 7.9, 0.4 μM: 58.3 ± 7.7 |
HCT8 | 2.1±1.6 | 32.3 ± 4.1 | DSF/Cu 0.05 μM: 29.5 ± 4.4, 0.1 μM: 28.1 ± 9.5, 0.2 μM: 38.6 ± 10.3, 0.4 μM: 56.4 ± 10.2 | ||||||
SW620 | 2.21±0.5 | 48.4 ± 9.5 | DSF/Cu 0.05 μM: 20.1±5.7, 0.1 μM: 30 ± 4.2, 0.2 μM: 42 ± 6.3, 0.4 μM: 43.45 ± 8.3 | ||||||
Yang et al. | Germany | Breast cancer | 48 h | Control | CIS (5 μM) | MCF-7 | 25.31 | 31.67 | DSF 1 μM: 36.6, DSF 1 μM + CIS 5 μM: 57.4 |
MDA-MB-435S | 5.843 | 5.447 | DSF 1 μM: 13.56, DSF 1 μM + CIS 5 μM: 29.4 | ||||||
SKB-R3 | 3.023 | 11.46 | DSF 1 μM: 5.6, DSF 1 μM + CIS 5 μM: 7.71 | ||||||
Wu et al. | China | Triple-negative breast cancer | 24 h | DMSO | PAX (5 nM) | SUM102 ALDH+ | 2.22 | 5.83 | DSF/Cu 0.75 μM: 23.53 |
SUM102 ALDH- | 8.01 | 10.81 | DSF/Cu 0.75 μM: 20.9 | ||||||
Guo et al. | Germany | Ovarian cancer | 72 h | Control | _ | IGROV1 | 10.32 | _ | Cu 1 μM: 15.3, DSF 1 μM: 25.46, DSF/Cu: 47.55 |
SKOV3IP1 | 8.69 | Cu 1 μM: 7.1, DSF 0.1 μM: 15.99, DSF/Cu: 55 | |||||||
SKOV3 | 3.65 | Cu 1 μM: 1.91, DSF 1 μM: 43.2, DSF/Cu: 50.4 | |||||||
Wu et al. | China | Non-small cell lung cancer | 24 h | Control | _ | A549 | 2.5 | _ | Cu 1 μM: 3.8, DSF 1.4 μM: 4.8, DSF/Cu: 35.4 |
H460 | 4.7 | Cu 1 μM: 3.7, DSF 8 μM: 4.9, DSF/Cu: 21.4 | |||||||
H1299 | 8.7 | Cu 1 μM: 10.3, DSF 4 μM: 7.1, DSF/Cu: 37.9 | |||||||
Chen et al. | China | Non-small cell lung cancer | 24 h | Control | _ | A549 | 3.35 | _ | Ag 1.25 μM: 4.34, DSF 1.25 μM: 5.14, DSF/Ag: 42.81 |
Butcher et al. | UK | Non-small cell lung cancer | 16 h | Vehicle | _ | A549 | 6.3 | _ | CuCl2 10 μM: 6.5, DSF 1 μM: 15.2, DSF/CuCL2: 47.2 |
Albers et al. | Germany | Head and neck squamous | 48 h | Control | CIS (1μM)+10Gy | HNSCC cell lines | 11.35 | CIS 1 μM: 24.12, 10Gy: 23.47 | DSF 3 μM/Cu 0.1 μM: 20.87, DSF 3 μM + CIS 1 μM: 38.35, DSF 3 μM/Cu 0.1 μM + CIS 1 μM: 51 |
cell carcinoma | CIS 1 μM + 10Gy: 30.68 | DSF 3 μM: 17.66, CIS 1 μM + 10Gy+ DSF 3 μM: 44.82, CIS 1 μM + 10Gy+ DSF 3 μM/Cu 0.1 μM: 61.5 | |||||||
Yang et al. | China | Nasopharyngeal cancer | 6 h | Control | _ | CNE-2Z | 4.41 | _ | DSF 0.2 μM/Cu 10 μM: 24.08, DSF 0.4 μM/Cu 10 μM: 58.2 |
NP69-SV40T | 0.55 | _ | DSF 0.2 μM/Cu 10 μM: 1.19, DSF 0.4 μM/Cu 10 μM: 5.99 | ||||||
Marwa et al. | Egypt | Colon cancer | 72 h | Control | _ | DCECs | 1.58 | _ | DSF 9.5 ± 0.9 μg/mL: 60.31 ± 1.2, UC-NPs 1548.7 ± 25 μg/mL: 12.12 ± 0.47, C-NPs 3122.4 ± 39 μg/mL: 2.6 ± 0.07 |
CDCECs | 0.28 | _ | DSF 23.9 ± 0.1 μg/mL: 57.78 ± 0.34, UC-NPs 77.7 ± 1.4 μg/mL: 54.75 ± 1.24, C-NPs 93.8 ± 0.4 μg/mL: 47.5 ± 0.31 | ||||||
Caco-2 | 0.05 | _ | DSF 39.6 ± 0.3 μg/mL: 53.62 ± 0.53, UC-NPs 97.9 ± 0.5 μg/mL: 53.49 ± 0.59, C-NPs 148.3 ± 0.1 μg/mL: 40.28 ± 0.24 | ||||||
Wang et al. | China | Non-small cell lung cancer | 24 h | Control | _ | A549 | 0.45 | _ | DSF-LP-PLGA-MP 1, 3, 5, 7days: 9.32, 27.1, 28.2, 49.18 |
Yang et al. | China | Breast cancer | 24 h | Control | _ | MCF-7 | 0.29 | _ | DSF 0.2 μM/CuCl2 10 μM: 27.56, DSF 0.25μM/CuCl2 10 μM: 86.8 |
Kim et al. | Korea | HER2-positive breast cancer | 24 h | DMSO | _ | SKBR3 | 3.16 | _ | Cu 1 μM: 2.91, DSF 1 μM: 2.6, DSF/Cu: 30.21 |
BT474 | 2.49 | _ | Cu 1 μM: 2.88, DSF 1 μM: 8, DSF/Cu: 40.76 | ||||||
Sharma et al. | India | Prostatic cancer | 48 h | Control | STA (3mM) | PC3 | 8.34±2.2 | 26.31±5.5 | DSF 1 μM: 15.04±3.14, DSF 2 μM: 19.71±4.2, DSF 3 μM: 32.06±6.16 |
DU145 | 13.67±2.66 | 41.31±4.47 | DSF 1 μM: 10.89±1.56, DSF 2 μM: 42.81±4.56, DSF 3 μM: 47.23±4.85 | ||||||
Zhao et al. | China | Pituitary adenomas | 24 h | Control | TMZ (100μM) | Pituitary adenoma cells | 0.29±0.09 | 0.81±0.23 | DSF 25 μM: 0.31±0.10, DSF 25 μM + TMZ 100 μM: 1.64±0.16 |
Zhang et al. | China | Hepatocellular carcinoma | 24 h | Control | _ | Hep G2 cells | 1.3 | _ | DSF-S-LNCs (PH = 7.4) : 9.4, DSF-S-LNCs (PH = 6.5) : 16.5 |
Duan et al. | China | Breast cancer | 24 h | Control | _ | 4T1 | 1.07 | _ | DSF 1 μg: 34.77, DnMs (DSF 1 μg): 34.37, DCM (DSF 1 μg): 41.11 |
Rezk et al. | USA | Ovarian cancer | 72 h | Control | _ | A2780DK | 4.15 | _ | DSF 5 μM: 36.4 |
Dastjerdi et al. | Iran | Pancreatic cancer | 24 h | Control | _ | PANC-1 | 27 | _ | DSF 5 μM: 51, DSF 10 μM: 84, DSF 13 μM: 92 |
Han et al. | China | Pancreatic cancer | 72 h | Control | _ | SW1990 | 1.5 | _ | DDTC–Cu(I) 1 μM: 6.4, DDTC–Cu(I) 3 μM: 17.7, DDTC–Cu(I) 5 μM: 24.8 |
Cen et al. | USA | Melanoma | 48 h | Control | BSO (100M) | C81-46A | 12.057±0.72 | 13.194±1.11 | DSF 50 ng/ml: 25.35 ± 1.21, DSF 50 ng/ml + BSO 100 M: 54.78 ± 2.83 |